KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Liabilities and Shareholders Equity (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 16 years of Liabilities and Shareholders Equity data on record, last reported at $40.2 billion in Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity rose 7.28% year-over-year to $40.2 billion; the TTM value through Dec 2025 reached $115.9 billion, up 54.16%, while the annual FY2024 figure was $37.8 billion, 14.15% up from the prior year.
  • Liabilities and Shareholders Equity reached $40.2 billion in Q3 2025 per REGN's latest filing, up from $38.2 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $40.2 billion in Q3 2025 and bottomed at $27.2 billion in Q2 2022.
  • Average Liabilities and Shareholders Equity over 4 years is $33.4 billion, with a median of $32.6 billion recorded in 2023.
  • Peak YoY movement for Liabilities and Shareholders Equity: rose 16.41% in 2024, then grew 7.28% in 2025.
  • A 4-year view of Liabilities and Shareholders Equity shows it stood at $29.2 billion in 2022, then increased by 13.23% to $33.1 billion in 2023, then grew by 14.15% to $37.8 billion in 2024, then increased by 6.38% to $40.2 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $40.2 billion in Q3 2025, $38.2 billion in Q2 2025, and $37.5 billion in Q1 2025.